Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - DYNASIL CORP OF AMERICA | Financial_Report.xls |
| 10-K - FORM 10-K - DYNASIL CORP OF AMERICA | v395895_10k.htm |
| EX-21.1 - EXHIBIT 21.1 - DYNASIL CORP OF AMERICA | v395895_ex21-1.htm |
| EX-32.1 - EXHIBIT 32.1 - DYNASIL CORP OF AMERICA | v395895_ex32-1.htm |
| EX-31.1B - EXHIBIT 31.1B - DYNASIL CORP OF AMERICA | v395895_ex31-1b.htm |
| EX-23.1 - EXHIBIT 23.1 - DYNASIL CORP OF AMERICA | v395895_ex23-1.htm |
| EX-31.1A - EXHIBIT 31.1A - DYNASIL CORP OF AMERICA | v395895_ex31-1a.htm |
Exhibit 99.1
Contacts:
Patty Kehe
Corporate Secretary
Dynasil Corporation of America
Phone: 617.668.6855
pkehe@dynasil.com
Dynasil
Corporation of America Reports
Fiscal Year 2014 Financial Results
Company reports $2.0 million of net income for fiscal 2014
Newton, MA, December 16, 2014 Dynasil Corporation of
America (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology
and components for the homeland security, medical and industrial markets, today announced net income of $2.0 million or $0.13 per
common share for the fiscal year ended September 30, 2014 and the filing of its Annual Report on Form 10-K.
“We successfully completed the restructuring of the Company which we started last year,” reported Peter Sulick, Chairman
and CEO. “During 2014, we sold our lead paint and gamma medical probe businesses, refinanced senior debt which had been in
default, reduced our total outstanding debt to $5.6 million from $9.8 million, added needed capacity to our optical coatings business
by acquiring DichroTec Thin Films, LLC and returned the Company to profitability. I am particularly excited to report that our
four optics business units grew their revenues by 19% in 2014 which substantially offset the revenues associated with the two instrument
businesses we sold. In fact, we achieved record revenues at three of our optics business units and saw a substantial increase at
the fourth. We believe these business units will continue to generate solid revenue growth in 2015 and beyond.”
“We also completed the spin out of our tissue sealant technology to the newly-formed joint venture, Xcede Technologies, and raised $1.4 million of convertible notes from external investors, including officers and directors of the Company, during fiscal year 2014 to fund on-going development of this exciting new technology.” Continued Mr. Sulick, “Xcede expects to begin its first in human trials during 2015.”
Net income in 2014 was $2.0 million or $0.13 per common share compared to a net loss of $8.7 million or $0.59 per common share in 2013. The net income in 2014 included a $1.3 million gain from the sale of two businesses while the net loss in 2013 included an asset impairment charge of $6.8 million. Excluding the gain on sale in 2014 and the asset impairment charge in 2013, our adjusted net income was $0.7 million in 2014 compared to a loss of $1.9 million in 2013. Our net income in both years was reduced by approximately $0.8 million of losses from our Biomedical segment, which includes the results of the newly formed Xcede Technologies in 2014.
Revenues declined $0.5 million to $42.3 million in 2014 compared to $42.8 million in 2013. Excluding the revenues of the Instruments businesses which were sold in the first quarter of 2014, our adjusted revenues increased 10.3% to $41.5 million in 2014 from $37.6 million in 2013 primarily due to revenue volume growth across all four business units in the Optics segment.
Gross profit for fiscal year 2014 decreased $1.4 million or 7.5% to $16.7 million from the prior year amount of $18.1 million. Gross profit as a percentage of revenue decreased to 39.5% from 42.3% at September 30, 2013 primarily as a result of higher gross profit margins from the Instruments businesses that were sold in the first quarter of fiscal year 2014. Excluding the Instruments businesses, adjusted gross profit increased $0.7 million or 4.8% to $16.4 million in 2014 from $15.7 million in 2013.
Total operating expenses decreased $12.2 million to $14.0 million or 33.2% of revenue in 2014, from $26.2 million in 2013. Total operating expenses included a $1.3 million gain from the sale of the Instruments businesses in 2014 and a $6.8 million asset impairment charge in 2013. Excluding the gain on sale in 2014 and the asset impairment charge in 2013, adjusted total operating expenses decreased $4.1 million primarily as a result of the lower costs resulting from the sale of the Instruments businesses in the first quarter of 2014 and also associated with the Instruments businesses which were sold in the first quarter of fiscal year 2014 as well as cost savings in the Contract Research segment in 2014.
Conference Call Information
Dynasil will host a conference call for investors and analysts at 4:15 p.m. ET today. The call will be hosted by Chairman, CEO and President Peter Sulick and Chief Financial Officer Thomas Leonard. Those who wish to listen to the conference call can go to the event page at http://www.videonewswire.com/event.asp?id=101147 or visit the Investor Information section of the Company’s website at www.dynasil.com. The call also may be accessed by dialing (888) 346-2613 or (412) 902-4252. For interested individuals unable to join the live conference call, a webcast replay will be available on the Company’s website for one year.
Use of Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release also contains (i) a measure of our net income excluding the gain on sale of our lead paint and gamma medical probe businesses and our net loss excluding asset impairment charges and (ii) a measure of adjusted revenues, adjusted gross profits and adjusted SG&A expenses for fiscal years 2014 and 2013 depicting revenues, gross profit and SG&A expenses “as if” the Instruments businesses which were sold in the first quarter of 2014 had been sold prior to the start of fiscal year 2013. The Company believes that the inclusion of these non-GAAP financial measures help investors to gain a meaningful understanding of the Company’s core operating results and enhances comparing such performance with prior periods. Our management uses these non-GAAP measures, in addition to GAAP financial measures, as the basis for measuring our core operating performance and comparing such performance to that of prior periods. The non-GAAP financial measures included in this press release are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP.
About Dynasil
Dynasil Corporation of America (NASDAQ: DYSL) develops and manufactures optical detection and analysis technology and components for the homeland security, medical and industrial markets. Combining world-class expertise in research and materials science with extensive experience in manufacturing and product development, Dynasil is commercializing products including dual-mode radiation detection solutions for Homeland Security and commercial applications and sensors for non-destructive testing. Dynasil has an impressive and growing portfolio of issued and pending U.S. patents. The Company is based in Newton, Massachusetts, with additional operations in Mass., Minn., NY, NJ and the United Kingdom. More information about the Company is available at www.dynasil.com.
Forward-looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of our management, including, without limitation, our expectations regarding future events and our future results are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of our management, including, without limitation, our expectations regarding results of operations, our compliance with the financial covenants under our loan agreements with Middlesex Savings Bank and Massachusetts Capital Resource Company, Xcede obtaining financing from outside investors, the commercialization of our products including our dual mode detectors, our development of new technologies including at Dynasil Biomedical, uncertainty of the impact of the DichroTec acquisition, the adequacy of our current financing sources to fund our current operations, our growth initiatives, our capital expenditures and the strength of our intellectual property portfolio. These forward-looking statements may be identified by the use of words such as “plans,” “intends,” “may,” “could,” “expect,” “estimate,” “anticipate,” “continue” or similar terms, though not all forward-looking statements contain such words. The actual results of the future events described in such forward looking statements could differ materially from those stated in such forward looking statements due to a number of important factors. These factors that could cause actual results to differ from those anticipated or predicted include, without limitation, our ability to comply with the financial covenants under our outstanding indebtedness, our ability to develop and commercialize our products, including obtaining regulatory approvals, the size and growth of the potential markets for our products and our ability to serve those markets, the rate and degree of market acceptance of any of our products, general economic conditions, costs and availability of raw materials and management information systems, our ability to obtain and maintain intellectual property protection for our products, competition, the loss of key management and technical personnel, our ability to obtain timely payment of our invoices to governmental customers, litigation, the effect of governmental regulatory developments, the availability of financing sources, our ability to identify and execute on acquisition opportunities and integrate such acquisitions into our business, and seasonality, as well as the uncertainties set forth in the Company’s Annual Report on Form 10-K and from time to time in the Company's other filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
DYNASIL CORPORATION OF AMERICA AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
| September 30, 2014 | September 30, 2013 | |||||||
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 3,842,000 | $ | 2,437,000 | ||||
| Accounts receivable, net | 3,240,000 | 3,657,000 | ||||||
| Costs in excess of billings and unbilled receivables | 1,235,000 | 1,537,000 | ||||||
| Inventories, net of reserves | 2,954,000 | 3,140,000 | ||||||
| Prepaid expenses and other current assets | 919,000 | 1,292,000 | ||||||
| Total current assets | 12,190,000 | 12,063,000 | ||||||
| Property, Plant and Equipment, net | 6,518,000 | 4,774,000 | ||||||
| Other Assets | ||||||||
| Intangibles, net | 1,383,000 | 3,485,000 | ||||||
| Goodwill | 6,247,000 | 6,241,000 | ||||||
| Deferred financing costs, net | 39,000 | 114,000 | ||||||
| Total other assets | 7,669,000 | 9,840,000 | ||||||
| Total Assets | $ | 26,377,000 | $ | 26,677,000 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current Liabilities | ||||||||
| Current portion of long-term debt | $ | 2,329,000 | $ | 9,819,000 | ||||
| Capital lease obligations, current | 134,000 | 124,000 | ||||||
| Convertible notes | 1,433,000 | - | ||||||
| Accounts payable | 1,602,000 | 2,056,000 | ||||||
| Deferred revenue | 103,000 | 516,000 | ||||||
| Accrued expenses and other liabilities | 2,503,000 | 2,847,000 | ||||||
| Total current liabilities | 8,104,000 | 15,362,000 | ||||||
| Long-term Liabilities | ||||||||
| Long-term debt, net of current portion | 3,282,000 | - | ||||||
| Capital lease obligations, net of current portion | 95,000 | 232,000 | ||||||
| Pension liability | 318,000 | 250,000 | ||||||
| Deferred tax liability | 264,000 | 187,000 | ||||||
| Total long-term liabilities | 3,899,000 | 669,000 | ||||||
| Stockholders' Equity | ||||||||
| Dynasil stockholders’ equity | 14,383,000 | 10,646,000 | ||||||
| Noncontrolling interest | (69,000 | ) | - | |||||
| Total stockholder’s equity | 14,314,000 | 10,646,000 | ||||||
| Total Liabilities and Stockholders' Equity | $ | 26,377,000 | $ | 26,677,000 | ||||
DYNASIL CORPORATION OF AMERICA
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
| 2014 | 2013 | |||||||
| Net revenue | $ | 42,309,000 | $ | 42,753,000 | ||||
| Cost of revenue | 25,579,000 | 24,667,000 | ||||||
| Gross profit | 16,730,000 | 18,086,000 | ||||||
| Operating expenses: | ||||||||
| Sales and marketing | 1,408,000 | 1,747,000 | ||||||
| Research and development | 1,343,000 | 2,307,000 | ||||||
| General and administrative | 12,581,000 | 15,372,000 | ||||||
| Gain on sale of assets | (1,297,000 | ) | - | |||||
| Impairment of goodwill and long-lived assets | - | 6,829,000 | ||||||
| Total operating expenses | 14,035,000 | 26,255,000 | ||||||
| Income (loss) from operations | 2,695,000 | (8,169,000 | ) | |||||
| Interest expense, net | 713,000 | 861,000 | ||||||
| Income (loss) before taxes | 1,982,000 | (9,030,000 | ) | |||||
| Income tax (credit) | (21,000 | ) | (303,000 | ) | ||||
| Net income (loss) | 2,003,000 | (8,727,000 | ) | |||||
| Less: Net loss attributable to noncontrolling interest | (69,000 | ) | - | |||||
| Net income (loss) attributable to common stockholders | $ | 2,072,000 | $ | (8,727,000 | ) | |||
| Net income (loss) | $ | 2,003,000 | $ | (8,727,000 | ) | |||
| Other comprehensive income (loss): | ||||||||
| (Increase) decrease in pension liability | (68,000 | ) | 93,000 | |||||
| Foreign currency translation | 13,000 | (2,000 | ) | |||||
| Total comprehensive income (loss) | $ | 1,948,000 | $ | (8,636,000 | ) | |||
| Basic net income (loss) per common share | $ | 0.13 | $ | (0.59 | ) | |||
| Diluted net income (loss) per common share | $ | 0.13 | $ | (0.59 | ) | |||
| Weighted average shares outstanding | ||||||||
| Basic | 15,415,408 | 14,812,858 | ||||||
| Diluted | 15,429,664 | 14,812,858 | ||||||